Nesrallah Gihad, Mendelssohn David C
Department of Nephrology, Humber River Regional Hospital, Toronto, ON, Canada.
Hemodial Int. 2006 Apr;10(2):143-51. doi: 10.1111/j.1542-4758.2006.00086.x.
As the End-stage renal disease population continues to grow, innovative strategies that optimize patient outcomes while capitalizing on the relative strengths of the existing modalities must be sought. Renal transplantation remains the preferred form of renal replacement therapy, but given the limited supply of donor organs, dialytic therapies will continue to constitute a large part of the modality mix. Matching patients to the most suitable modalities requires that a number of factors be considered. These include the patient's autonomy, medical and social factors, system-related issues, patient outcomes, and finances. While peritoneal dialysis and hemodialysis (HD) have traditionally been viewed as competing modalities, we propose that they, along with home and frequent HD regimens, may be used in a complementary manner, which is based on current evidence, and may provide optimal outcomes while containing treatment costs. In this review, we attempt to synthesize the current literature describing the various issues that affect modality selection, and offer an approach to achieving a balance between these many competing factors.
随着终末期肾病患者群体持续增长,必须寻求创新策略,在利用现有治疗方式相对优势的同时优化患者治疗效果。肾移植仍然是肾替代治疗的首选方式,但鉴于供体器官供应有限,透析治疗仍将在治疗方式组合中占很大比例。为患者匹配最合适的治疗方式需要考虑多个因素。这些因素包括患者的自主性、医疗和社会因素、系统相关问题、患者治疗效果及经济状况。虽然传统上腹膜透析和血液透析(HD)被视为相互竞争的治疗方式,但我们认为,基于现有证据,它们与家庭及频繁血液透析方案可互补使用,在控制治疗成本的同时可能带来最佳治疗效果。在本综述中,我们试图综合描述影响治疗方式选择的各种问题的当前文献,并提供一种在诸多相互竞争的因素之间取得平衡的方法。